C&EN1mon
Molecular Design in Area-Selective Atomic Layer Deposition: Understanding Inhibitors and Precursors
Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...
C&EN1mon
Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors as Potential Treatment for Several Inflammatory and Neurodegenerative Diseases
These compounds have activities as receptor-interacting protein kinase 1 (RIPK1) inhibitors and may potentially provide treatment and/or prophylaxis of inflammatory and neurodegenerative diseases ...
STAT2mon
As targeted therapies prevail, patient voice and preference should, too
For coadministration with a moderate CYP3A inhibitor, reduce BRUKINSA dose to 80 mg twice daily. CYP3A Inducers: Avoid coadministration with strong or moderate CYP3A inducers. Dose adjustment ...
Frontiers8mon
Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease
Moreover, JAK inhibitors such as tofacitinib, peficitinib, upadacitinib and decucravacitinib are also good options for IBD treatment. Therefore, various antibodies blocking the activity of ...
eLife1y
AIDS virus-neutralizing antibody induction reciprocal to a PI3K gain-of-function disease
(B) Schema of SIV mac239 Nef structure and Nef-G63E mutation orientation. (C) Comparison of frequencies of macaques having Nef-G63E in plasma viruses between NAb non-inducers and inducers. Compared by ...
Frontiers2y
Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
Immune checkpointty inhibitors (ICIs), particularly those targeting programmed death 1 (PD-1) and anti-programmed death ligand 1 (PD-L1), enhance the antitumor effect by restoring the function of the ...